DarioHealth (NASDAQ:DRIO – Get Free Report) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it weigh in compared to its rivals? We will compare DarioHealth to similar companies based on the strength of its earnings, dividends, risk, valuation, analyst recommendations, profitability and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for DarioHealth and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DarioHealth | 1 | 1 | 3 | 0 | 2.40 |
| DarioHealth Competitors | 448 | 1520 | 2729 | 88 | 2.51 |
DarioHealth currently has a consensus price target of $9.00, suggesting a potential upside of 199.80%. As a group, “Healthcare Technology” companies have a potential upside of 37.97%. Given DarioHealth’s higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than its rivals.
Profitability
This table compares DarioHealth and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DarioHealth | -169.87% | -54.81% | -33.36% |
| DarioHealth Competitors | -778.93% | -33.97% | -15.65% |
Earnings & Valuation
This table compares DarioHealth and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| DarioHealth | $22.36 million | -$41.71 million | -0.49 |
| DarioHealth Competitors | $341.86 million | -$24.15 million | 13.10 |
DarioHealth’s rivals have higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
DarioHealth has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, DarioHealth’s rivals have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Insider and Institutional Ownership
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 42.3% of shares of all “Healthcare Technology” companies are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 16.0% of shares of all “Healthcare Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
DarioHealth rivals beat DarioHealth on 9 of the 13 factors compared.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
